Published Technical Disclosure Archive

Enhanced Molecular Imaging and Targeted Drug Delivery Systems

Publication ID: 24-11857648_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Molecular Imaging and Targeted Drug Delivery Systems,” Published Technical Disclosure No. 24-11857648_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857648_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,648.

Summary of the Inventive Concept

The present invention relates to improved molecular imaging and targeted drug delivery systems, addressing limitations of existing multivalent molecule approaches by introducing linker molecules, modular designs, polymeric backbones, high-throughput screening methods, and optimized kits.

Background and Problem Solved

The original patent disclosed multivalent molecular imaging and/or targeted drug delivery methods, but these approaches were limited by non-specific binding, poor cellular uptake, and stability issues. The new inventive concept addresses these limitations by introducing novel strategies for enhancing cellular uptake, reducing non-specific binding, and increasing stability.

Detailed Description of the Inventive Concept

The inventive concept comprises a multivalent molecule conjugated with a linker molecule that enhances cellular uptake and reduces non-specific binding. The molecule features a modular design, allowing for interchangeable biomarkers and imaging labels. Additionally, the molecule can be constructed with a polymeric backbone, providing increased stability and prolonged retention in vivo. High-throughput screening methods utilizing microarray platforms with immobilized biomarkers enable efficient identification of optimal compounds. Finally, optimized kits comprising the multivalent molecule, detectable label, and spacer molecule facilitate straightforward use.

Novelty and Inventive Step

The new inventive concept introduces novel linker molecules, modular designs, and polymeric backbones that significantly improve the performance and stability of multivalent molecular imaging and targeted drug delivery systems. These innovations provide a non-obvious solution to the limitations of the original patent, offering enhanced cellular uptake, reduced non-specific binding, and increased stability.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include variations in linker molecule structures, modular design configurations, and polymeric backbone compositions. Additional variations may involve the use of different biomarkers, imaging labels, and spacer molecules to tailor the system to specific applications.

Potential Commercial Applications and Market

The enhanced molecular imaging and targeted drug delivery systems have significant commercial potential in the fields of cancer diagnosis and treatment, infectious disease imaging, and personalized medicine. The market for these systems is expected to grow rapidly, driven by the need for more effective and targeted therapies.

CPC Classifications

SectionClassGroup
A A61 A61K51/082
A A61 A61K9/51
A A61 A61K47/6893
A A61 A61K51/1027
C C07 C07D255/02
C C07 C07D257/02
C C07 C07K7/06
C C07 C07K7/64
C C07 C07K16/30
G G01 G01N33/5008
G G01 G01N33/60
C C07 C07K2319/00

Field of Art

Molecular imaging, radiopharmaceuticals, and targeted drug delivery systems, involving peptide conjugation, chelator chemistry, and diagnostic/therapeutic molecular design

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in chemistry, biochemistry, or chemical engineering, possessing expertise in peptide synthesis, radioisotope labeling, molecular conjugation techniques, and biomedical imaging technologies

Obviousness Rationale

A PHOSITA would recognize that the published technical disclosure represents predictable variations of the source patent's core molecular imaging strategy by introducing modular design principles, linker molecules, and systematic optimization approaches that are well-established in molecular conjugation technologies. The disclosed improvements represent incremental engineering adaptations that would be obvious to implement using standard techniques in peptide and molecular imaging research. The variations demonstrate routine application of known methodological enhancements to an existing molecular targeting framework.

Obvious Combinations & Variations

Source Patent Element
Multivalent molecule with peptide components and chelator for molecular imaging
PTD Variation
Introduction of linker molecules to enhance cellular uptake and reduce non-specific binding
Obviousness Reasoning
Modifying molecular targeting strategies with linker molecules is a known technique for improving cellular interaction, representing a predictable optimization approach within molecular imaging design
Source Patent Element
Compounds using specific detectable labels like Cy3, Cy5, and radioisotopes
PTD Variation
Implementing modular design allowing interchangeable biomarkers and imaging labels
Obviousness Reasoning
Creating modular molecular platforms is a standard design strategy in biomedical engineering, enabling systematic exploration of different molecular configurations with expected and predictable results
Source Patent Element
Molecular imaging compounds with peptide and chelator components
PTD Variation
Incorporating polymeric backbones to increase stability and in vivo retention
Obviousness Reasoning
Utilizing polymeric structures to enhance molecular stability is a well-known approach in drug delivery and imaging technologies, representing an obvious extension of existing molecular design principles
Source Patent Element
Molecular imaging compounds with specific chelator selections
PTD Variation
High-throughput screening methods using microarray platforms with immobilized biomarkers
Obviousness Reasoning
Implementing systematic screening techniques is a standard research methodology for optimizing molecular targeting compounds, representing an expected technological progression
Source Patent Element
Molecular imaging compounds with multiple component configurations
PTD Variation
Development of comprehensive kits with multivalent molecules, detectable labels, and spacer molecules
Obviousness Reasoning
Creating standardized research kits is a routine approach in biotechnology for facilitating reproducible experimental protocols, representing an obvious commercial and research optimization
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in the published technical disclosure would have been obvious to a person having ordinary skill in the art at the time of invention, with a reasonable expectation of success, when considering the teachings of US Patent 11857648. The incremental improvements represent predictable variations within the established molecular imaging technological domain, demonstrating that the claimed innovations would have been obvious to a skilled practitioner through routine engineering modifications and standard design optimization strategies.

Original Patent Information

Patent NumberUS 11,857,648
TitleDimerization strategies and compounds for molecular imaging and/or radioimmunotherapy
Assignee(s)UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION